|
|
|
|
|
|
CLINICAL DEVELOPMENT STRATEGY
When entering a new therapeutic area hinged on a well-reasoned clinical development strategy
and market assessment, a large biotech company relied on Health Advances to show the way.
CML DRUG DEVELOPMENT
When an emerging biotechnology company with a promising tyrosine kinase inhibitor (TKI) suitable for
multiple patient populations needed a strategy to maximize clinical development dollars and generate
positive returns, Health Advances was the firm of choice.
COMMERCIALIZATION STRATEGY
Facing multiple possible lead indications, we helped our client define a logical
development path to minimize risk and optimize value.
DIAGNOSTICS INDUSTRY STRATEGY
When the senior management team of a Fortune 500 diagnostics company needed an
advisor to challenge their thinking and develop an acquisition strategy, they
sought out Health Advances.
FRANCHISE STRATEGY
From defining a vision to completing a major acquisition, Health Advances was there
to assist our client with every step in building a formidable CNS franchise.
NSCLC TREATMENT PATHWAY
Faced with the prospect of having to reset revenue expectations for its entire portfolio of
lung cancer targeted agents, a large biotechnology company turned to Health Advances to
identify the drivers and barriers to lung cancer treatment and strategies to overcome the
low overall treatment rate.
PORTFOLIO PRIORITIZATION
Facing multiple possible lead indications, we helped our client define a logical
development path to minimize risk and optimize value.
REIMBURSEMENT AND PRICING STRATEGY
Pricing considerations influence almost every decision. Prior to launching a novel
oncology drug for the first of four indications, our client required a clear strategy
to optimize the initial launch price.
DIAGNOSTIC ASSAY GLOBAL LAUNCH (PDF: 198KB)
Worldwide commercialization of an HIV diagnostic assay.
GLOBAL INSULIN STRATEGY (PDF: 35KB)
Developing a global insulin strategy for a major pharmaceutical company.
GLOBAL MANUFACTURING CAPACITY FORECAST (PDF: 35KB)
Determining worldwide manufacturing capacity requirements and the likely demand for outsourced manufacturing of therapeutic proteins.
NEW PRODUCT FORECAST IN DEVELOPING COUNTRIES (PDF: 23KB)
Forecasting the uptake of a novel infectious disease testing platform for rural regions in developing countries.
PROGRESS ASSESSMENT FOR A GLOBAL HEALTH ORGANIZATION (PDF: 44KB)
Independent evaluation of the impact of an international nonprofit organization and its plans for the future.
|
|
 |
|
|
|
|
